X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025)
X4 Pharmaceuticals (XFOR) reported Revenue of $2.6 million for Q4 2025, up 79.08% on a YoY basis from $1.4 million in Q4 2024, and up 45.5% quarter-over-quarter from $1.8 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Revenue for 4 years, with the latest figure at $2.6 million in Q4 2025.
- For the quarter ending Q4 2025, Revenue rose 79.08% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $35.1 million (up 1273.21% YoY), and the FY2025 full-year result was $35.1 million, up 1273.21% from the prior year.
- Revenue for Q4 2025 stood at $2.6 million, up from $1.8 million in the prior quarter.
- The five-year high for Revenue was $28.8 million in Q1 2025, with the low at $560000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | X4 Pharmaceuticals | 177.84 Mn | 177.84 Mn | 2.20 Mn | 2.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 28.81 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2018 | 3.50 Mn |